

CS/NSE&BSE/RPT/2020-21
November 25, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

.....

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions on a consolidated basis and balances for the half-year ended 30th September, 2020.

We request you to take this document on your record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



K. Hanumantha Rao
Company Secretary

Encl: as above

Suven Pharmaceuticals Limited

Disclosure of related party transactions on a consolidated basis

List of related parties on consolidated basis as per Reg. 23(9)

(a) Holding Company

Jasti Property and Equity Holdings Private Limited
(Holding in its capacity as sole trustee of Jasti Family Trust)

(b) Subsidiaries

Suven Pharma, Inc. (USA)

(c) Associates

Rising Pharma Holdings, Inc. (USA)

(d) Key Management personnel (KMP)

Mr. Venkateswarlu Jasti	Chairman & Managing Director
Mr. D. G. Prasad	Independent Director
Dr. Srivari Chandrasekhar	Independent Director
Ms. Deepanwita Chattopadhyay	Independent Director
Mr. J. V. Ramudu	Non-executive Director
Dr. Jerry Jeyasingh	Non-executive Director

(e) Relative of Key Management personnel

Mrs. Kalyani Jasti	Daughter of Mr. Venkateswarlu Jasti
--------------------	-------------------------------------

(f) Entity with common Control

Suven Life Sciences Limited
Suven Neurosciences, Inc. (USA)

Suven Pharmaceuticals Limited

Transactions during the half-year ended 30 September, 2020 with related parties

Particulars	<i>Rupees in lakhs</i>
	For the half-year ended 30 September 2020
Parent entities	
<ul style="list-style-type: none"> • Jasti Property and Equity Holdings Private Limited <i>(Holding in its capacity as sole trustee of Jasti Family Trust)</i> 	60.00%
Subsidiaries	
<ul style="list-style-type: none"> • Balance outstanding 	24557.68
Key Management Personnel compensation	
<ul style="list-style-type: none"> • Short term employee benefits 	458.49
<ul style="list-style-type: none"> • Balance outstanding 	196.56
Relative of Key Management Personnel compensation	
<ul style="list-style-type: none"> • Short term employee benefits 	119.58
Entity with common Control	
<ul style="list-style-type: none"> • Facility charges received from Suven Life Sciences Limited 	51.79
<ul style="list-style-type: none"> • Inter Company Loan received from Suven Life Sciences Limited 	9701.82
<ul style="list-style-type: none"> • Services received from Suven Life Sciences Limited 	114.81

Suven Pharmaceuticals Limited